<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04093427</url>
  </required_header>
  <id_info>
    <org_study_id>WI_19-090_softSTOPP</org_study_id>
    <nct_id>NCT04093427</nct_id>
  </id_info>
  <brief_title>Influence of an Inverse Pressure Ramp in Long-term Non-invasive Ventilation on Dyspnea in the Morning After Therapy</brief_title>
  <official_title>Einfluss Einer Inversen Druckrampe Bei Der Langzeit-Therapie Mit Nicht-invasiver Ventilation Auf Dyspnoe am Morgen Nach Therapie-Ende. Influence of an Inverse Pressure Ramp in the Long-term Therapy Mit Non-invasive Ventilation on Dyspnea in the Morning After Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wissenschaftliches Institut Bethanien e.V</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Löwenstein Medical Technology GmbH &amp; Co. KG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wissenschaftliches Institut Bethanien e.V</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients being treated with non-invasive home mechanical ventilation (NIV) may experience
      morning dyspnea after each night of NIV use, when the therapy is abruptly ended. This study
      aims to show that dyspnea intensity can be significantly reduced by a gentle NIV therapy end,
      delivered by a continuously decreasing pressure level (inverse pressure ramp) after therapy
      end in the morning, a feature called softSTOPP, which can configured in prismaVENT NIV
      devices. This could also improve therapy adherence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of dyspnea level from baseline to 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Delta value of morning dyspnea from baseline to 12 weeks as measured by the Borg Scale. The Borg Scale ranges from 0 (no perceived dyspnea at all) to 10 (maximum perceived dyspnea).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Noninvasive Ventilation</condition>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>softSTOPP active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>softSTOPP inactive</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>softSTOPP</intervention_name>
    <description>Non-invasive ventilation device setting in prismaVENT 30 device enabling an inverse pressure ramp after therapy end</description>
    <arm_group_label>softSTOPP active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Diagnosis of a chronic obstructive pulmonary disease (COPD) with chronic hypercapnic
             insufficiency

          -  Therapy with prismaVENT 30, firmware V 3.3 or higher, mode S/T, stable device settings
             at the time of inclusion without need to adapt ventilation parameters

          -  May have co-existing obstructive sleep apnea syndrome

          -  Subjective dyspnea ≥3 (Borg scale) after end of ventilation therapy in the morning

          -  Written informed consent for study participation including data protection

        Exclusion Criteria:

          -  Missing written informed consent for study participation including data protection

          -  Contraindication for positive airway pressure therapy

          -  Use of the softSTOPP feature before study inclusion

          -  Participation in another study, which influences NIV therapy by defining device
             settings or titration

          -  Concomitant oxygen therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winfried J Randerath, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Bethanien</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcel Treml, Dr.</last_name>
    <phone>+4921263</phone>
    <phone_ext>6661</phone_ext>
    <email>marcel.treml@klinik-bethanien.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Krankenhaus Bethanien</name>
      <address>
        <city>Solingen</city>
        <state>NRW</state>
        <zip>42699</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcel Treml, Dr.</last_name>
      <phone>+4921263</phone>
      <phone_ext>6661</phone_ext>
      <email>marcel.treml@klinik-bethanien.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

